CureVac Announces Financial Results and Business Updates for the Third Quarter and First Nine Months of 2020
Operating result
Operating loss was €36.8 million and €63.2 million for the three and nine months ended September 30, 2020, respectively, representing an increase of €17.6 million and a decrease of €1.2 million, or an increase of 92% and a decrease of 2%, from -€19.2 million and -€64.4 million for the same periods in 2019, respectively.
COVID-19 prophylactic vaccine candidate: CVnCoV on track for advanced clinical testing
Interim Phase 1 data showed generally good tolerability for CVnCoV and strong antibody responses in addition to first indication of T cell activation
Stability confirmed for at least three months at standard refrigerator temperature and for up to 24 hours at room temperature
Pivotal Phase 2b/3 to be initiated shortly with 12µg dose
Agreement with European Commission to supply 225 million doses of CVnCoV and an option for an additional 180 million doses
Building a strong European manufacturing network to supply up to 300 million doses by end of 2021 and up to 600 million doses by the end of 2022
Phase 1 results for oncology lead candidate, CV8102, confirm tolerability and responses in additional cancer indication
Financials: Cash position of €892 million as of September 30, 2020
1 % CAPITAL
Operating result
Operating loss was €36.8 million and €63.2 million for the three and nine months ended September 30, 2020, respectively, representing an increase of €17.6 million and a decrease of €1.2 million, or an increase of 92% and a decrease of 2%, from -€19.2 million and -€64.4 million for the same periods in 2019, respectively.
COVID-19 prophylactic vaccine candidate: CVnCoV on track for advanced clinical testing
Interim Phase 1 data showed generally good tolerability for CVnCoV and strong antibody responses in addition to first indication of T cell activation
Stability confirmed for at least three months at standard refrigerator temperature and for up to 24 hours at room temperature
Pivotal Phase 2b/3 to be initiated shortly with 12µg dose
Agreement with European Commission to supply 225 million doses of CVnCoV and an option for an additional 180 million doses
Building a strong European manufacturing network to supply up to 300 million doses by end of 2021 and up to 600 million doses by the end of 2022
Phase 1 results for oncology lead candidate, CV8102, confirm tolerability and responses in additional cancer indication
Financials: Cash position of €892 million as of September 30, 2020
1 % CAPITAL
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.